Vaccine Distribution

Baroness Lawrence of Clarendon Excerpts

Thursday 6th January 2022 Lords Chamber

[Lord Ahmad of Wimbledon (Con)]

My Lords, I assure the noble Lord that we are working with the developing world. The noble Lord, Lord Bilimoria, just pointed to our partnership with India, which has been crucial in terms of distribution and manufacture. But we have provided, for example, technical support to develop business cases for the Biovac company to manufacture vaccines in South Africa, to the Institut Pasteur in Dakar, Senegal, and directly to the Moroccan Government. We are also ensuring that our bilateral donations are targeted to the developing world.

[Baroness Lawrence of Clarendon (Lab)]

My Lords, following on from the question from the noble Lord, Lord Campbell-Savours, do Her Majesty’s Government consider that vaccine manufacturers should release the IP of the vaccine to help reduce transmission and possibly prevent further variants developing, which would eventually affect the UK in the long run?

[Lord Ahmad of Wimbledon (Con)]

My Lords, I believe the noble Baroness is referring to the continuing discussions at the WTO on the intellectual property rights waiver proposed by South Africa and India. In this regard, we are continuing to engage directly with key partners at the World Health Organization, but the one caveat I would share is that there is no evidence that an IP waiver would help us meet that goal. The reality is that the proposal for the TRIPS waiver would actually dismantle to a certain extent the very framework that has helped produce Covid-19 vaccines at an unprecedented pace.